The stock of TG Therapeutics Inc (NASDAQ:TGTX) is a huge mover today! About 186,230 shares traded hands. TG Therapeutics Inc (NASDAQ:TGTX) has declined 41.54% since April 27, 2016 and is downtrending. It has underperformed by 46.77% the S&P500.
The move comes after 5 months positive chart setup for the $307.83M company. It was reported on Nov, 30 by Barchart.com. We have $6.18 PT which if reached, will make NASDAQ:TGTX worth $21.55 million more.
Analysts await TG Therapeutics Inc (NASDAQ:TGTX) to report earnings on March, 6. They expect $-0.36 earnings per share, up 2.70% or $0.01 from last year’s $-0.37 per share. After $-0.50 actual earnings per share reported by TG Therapeutics Inc for the previous quarter, Wall Street now forecasts -28.00% EPS growth.
TG Therapeutics Inc (NASDAQ:TGTX) Ratings Coverage
Out of 6 analysts covering TG Therapeutics (NASDAQ:TGTX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. TG Therapeutics has been the topic of 7 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, August 12. The rating was initiated by SunTrust with “Buy” on Friday, May 27. The stock of TG Therapeutics Inc (NASDAQ:TGTX) has “Outperform” rating given on Tuesday, December 1 by FBR Capital. As per Wednesday, August 12, the company rating was upgraded by Zacks. The stock of TG Therapeutics Inc (NASDAQ:TGTX) earned “Buy” rating by Brean Capital on Thursday, October 6. The company was initiated on Friday, May 27 by Suntrust Robinson. The stock has “Strong Buy” rating given by Raymond James on Wednesday, September 9.
According to Zacks Investment Research, “TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.”
Insitutional Activity: The institutional sentiment decreased to 0.67 in 2016 Q2. Its down 0.87, from 1.54 in 2016Q1. The ratio dropped, as 10 funds sold all TG Therapeutics Inc shares owned while 18 reduced positions. 14 funds bought stakes while 29 increased positions. They now own 29.49 million shares or 0.54% more from 29.33 million shares in 2016Q1.
Guggenheim Lc last reported 164,213 shares in the company. Bnp Paribas Arbitrage holds 1,435 shares or 0% of its portfolio. Numeric Invsts Lc, a Massachusetts-based fund reported 12,000 shares. Henderson Grp Public Limited holds 844 shares or 0% of its portfolio. Creative Planning has invested 0% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX). Blackrock Management has 0% invested in the company for 149,087 shares. Northern Trust holds 0% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX) for 460,288 shares. Teachers Retirement Of The State Of Kentucky accumulated 160,700 shares or 0.01% of the stock. Millennium Limited Liability Corp reported 198,298 shares or 0% of all its holdings. Rhumbline Advisers holds 0% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX) for 37,547 shares. Vanguard Group Inc Inc reported 1.48 million shares or 0% of all its holdings. Schwab Charles Investment Mngmt has 59,050 shares for 0% of their US portfolio. Stoneridge Invest Prns Llc has invested 0.27% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX). California Pub Employees Retirement last reported 124,800 shares in the company. Blackrock last reported 4,447 shares in the company.
Insider Transactions: Since July 5, 2016, the stock had 0 insider purchases, and 1 sale for $302,052 net activity. 50,426 shares with value of $302,052 were sold by Power Sean A on Tuesday, July 5.
More recent TG Therapeutics Inc (NASDAQ:TGTX) news were published by: Fool.com which released: “Why TG Therapeutics, Inc. Stock Is Dropping Today” on October 13, 2016. Also Globenewswire.com published the news titled: “TG Therapeutics, Inc. Announces Publication in Blood Describing a Novel …” on October 27, 2016. Globenewswire.com‘s news article titled: “TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2016 Financial …” with publication date: October 31, 2016 was also an interesting one.
TGTX Company Profile
TG Therapeutics, Inc. (TG), incorporated on May 18, 1993, is a biopharmaceutical firm focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Firm is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Firm is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Firm also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Firm also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.